Patent US2723247A successfully refreshed from Google Patents.
Patent US4816108A successfully refreshed from Google Patents.
Patent US4443428A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4443428A Expired / Lapsed US ⏱️ 0.0 years remaining

Extended action controlled release compositions

Assignee: Euro Celtique SA
•
Filing: 1982-06-21
•
Granted: 1984-04-17
•
Expires: 2002-06-21
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The action of controlled release medications is extended by incorporation into the controlled release matrix for a medication a mixture of the salt form of the medication with the free base form of the medication in a proportion of a 75-25% by weight of the salt form to 25-75% by weight of the free base form, the weight amounts being calculated with respect to the active base.

Inventors

  • 👤 Benjamin Oshlack
  • 👤 Stewart T. Leslie

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 05:51
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2095

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 162 words
On an extended action controlled release pharmaceutical composition for oral administration comprising a hydrated hydroxyalkylcellulose and hydrophobic 10 to 18 carbon atoms higher aliphatic alcohol or paraffin wax balanced matrix melt granulation pharmaceutically acceptable controlled release core or matrix for the oral administration of pharmaceutically active agents, said controlled release core or matrix providing upon oral ingestion thereof slow release in the body of pharmaceutically active agents distributed therein, the improvement wherein said composition comprises said controlled release core or matrix for oral administration having distributed therethrough a pharmaceutically effective amount of a pharmacologically active substance in salt form thereof and in the free base form thereof, said pharmaceutically effective amount comprising between about 75% and 25% by weight of a pharmaceutically acceptable salt form of said pharmacologically active substance and between about 25% and 75% by weight of the free base form of said pharmacologically active substance, the amounts being based on the pharmacologically active moiety of said pharmacologically active substance.
Claim 2
Dependent Claim 162 words
On an extended action controlled release pharmaceutical composition for oral administration comprising a hydrated hydroxyalkylcellulose and hydrophobic 10 to 18 carbon atoms higher aliphatic alcohol or paraffin wax balanced matrix melt granulation pharmaceutically acceptable controlled release core or matrix for the oral administration of pharmaceutically active agents, said controlled release core or matrix providing upon oral ingestion thereof slow release in the body of pharmaceutically active agents distributed therein, the improvement wherein said composition comprises said controlled release core or matrix for oral administration having distributed therethrough a pharmaceutically effective amount of a pharmacologically active substance in salt form thereof and in the free base form thereof, said pharmaceutically effective amount comprising between about 75% and 25% by weight of a pharmaceutically acceptable salt form of said pharmacologically active substance and between about 25% and 75% by weight of the free base form of said pharmacologically active substance, the amounts being based on the pharmacologically active moiety of said pharmacologically active substance.
Claim 3
Dependent Claim 16 words
Extended action controlled release composition according to claim 1 wherein said composition is in tablet form.
Claim 4
Dependent Claim 17 words
Extended action controlled release pharmaceutical composition according to claim 1 wherein said composition is in capsule form.
Claim 5
Dependent Claim 36 words
Extended action controlled release pharmaceutical composition according to claim 1 wherein the pharmacologically active substance is amitryptaline, atropine, chlorpheniramine, chlorpromizine, codeine, dexbrompheniramine, diphenylhydramine, doxilamine, ephedrine, hyoscyamine, morphine, oxycodone, papavarine, phenylpropanolamine, propranolol, quinidine, scopolamine, theophylline or thioridazine.
Claim 6
Dependent Claim 8 words
Composition according to claim 1 in tablet form.
Claim 7
Dependent Claim 8 words
Composition according to claim 5 in capsule form.
Claim 8
Dependent Claim 37 words
Composition according to claim 1 wherein the pharmaceutically effective amount of said pharmacologically active substance comprises between about 60% and 40% by weight of the salt form and about 40%-60% by weight of the free base form.
Claim 9
Dependent Claim 44 words
Extended action controlled release pharmaceutical composition according to claim 1 wherein said controlled release core or matrix for oral administration has distributed therethrough quinidine base and quinidine polygalacturonate or propranolol base and propranolol hydrochloride or theophylline and aminophylline or codeine base and codeine phosphate.
Claim 10
Dependent Claim 28 words
Extended action controlled release pharmaceutical composition according to claim 1 wherein said controlled release core or matrix for oral administration has distributed therethrough codeine base and codeine phosphate.

References Cited (Backward Citations)

US3525790A Cited
US3608063A Cited
US4235870A Cited
US3965256A Cited
US4179497A Cited
US3957995A Cited
US4049791A Cited
US4160020A Cited
US4116241A Cited
US4160452A Cited
US4138475A Cited
US4248858A Cited
US4304765A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-04-17 1987-10-17 1988-04-17 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-04-17 1991-10-17 1992-04-17 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-04-17 1995-10-17 1996-04-17 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag